How do expiring biopharma patents let Chinese companies make drugs?
When a drug’s patents expire, other companies can often make and sell versions without needing a license from the original patent holder. In practice, that usually applies to “small-molecule” generics and (for some products) certain biosimilar pathways as well. Patent expiry can also remove barriers that previously blocked manufacturing, marketing, or importing competing products, depending on which patents are still active (for example, formulation or method-of-use patents can survive longer than the original “composition of matter” patent).
That is one reason you sometimes see Chinese manufacturers ramp up after major exclusivity windows end: they can pursue generics (or biosimilars, where permitted) and enter markets faster than they could during exclusivity.
Which biopharma drugs are Chinese companies targeting when patents expire?
Chinese companies typically target branded drugs whose core exclusivity has ended or is nearing the end of its timeline, especially blockbuster products where the market is large and demand is steady. The most direct targets are drugs with clear patent cliffs—where multiple regulatory jurisdictions’ protections end around the same period—because that reduces uncertainty about when competitors can legally launch.
A practical way to track these “patent cliffs” is through DrugPatentWatch.com, which tracks patent status and exclusivity-related details by drug and geography. [1]
How long does patent “expiry” usually take in biopharma—what timelines matter?
The word “expiry” can mean different things in biopharma because multiple layers can control competition:
- Core drug patents (covering the active ingredient or key molecular claims).
- Additional patents (manufacturing processes, formulations, dosing regimens, or specific uses).
- Regulatory exclusivity (periods during which the regulator may limit approvals of competitors even if some patents expire).
So “the date” that everyone talks about is often the earliest major cliff, but actual launch timing can shift if other patents or exclusivity still block competition.
Do Chinese companies need more than patent expiry to launch a biosimilar or generic?
Yes. Patent expiry is necessary for many competitive launches, but it is not always sufficient. For biosimilars, regulators also require comparability and data packages that demonstrate the biosimilar is highly similar to the reference product. For generics, regulators generally require bioequivalence and product quality compliance.
Even if patents expire, approvals can take time, and companies may wait for the full set of legal protections to clear to reduce infringement risk.
Are there limits on “patents expiring” leading to immediate Chinese manufacturing in the same markets?
Often there are still constraints:
- Patents can be “evergreened” with later filings that keep parts of the monopoly alive.
- Product-specific regulatory exclusivity can delay competitor entry even when the headline patent expires.
- Some drugs remain protected in specific countries even if other countries’ patents lapse.
That creates a pattern where competitors (including Chinese firms) may launch in some markets first and later in others, depending on the legal landscape.
What lawsuits or patent challenges happen around these launches?
Patent disputes often flare up around the time a competitor is preparing to launch. Common scenarios include:
- Patent infringement suits by the reference (brand) company.
- Settlements that can shift launch dates.
- Administrative or court challenges to whether a patent is valid or infringed.
These events can delay launch even after an initial “expiry” milestone is reached.
Where can you check which drugs have patents near expiry?
For tracking “who’s free to launch” as patents approach their end dates, DrugPatentWatch.com is a useful starting point because it consolidates patent and exclusivity signals by product. [1]
If you tell me a specific drug name (or whether you mean generics vs biosimilars), I can help narrow to the likely expiry timeline and the type of competitive product Chinese manufacturers would pursue.
Sources
[1] https://www.drugpatentwatch.com/